“Increasing Adoption of Real-World Evidence (RWE) and Real-World Data (RWD)”
One of the emerging trends in the Global Health Economics and Outcomes Research (HEOR) services market is the increasing adoption of Real-World Evidence (RWE) and Real-World Data (RWD) in HEOR studies. RWE/RWD refers to data collected from real-world sources, such as electronic health records, claims databases, and patient registries, which provide valuable insights into the effectiveness and safety of healthcare interventions in real-world settings. This trend is driven by the need for more robust and generalizable evidence to support healthcare decision-making, as traditional randomized controlled trials (RCTs) may not fully capture the complexities of real-world healthcare settings. As a result, pharmaceutical and biotechnology companies, payers, and regulatory agencies are increasingly leveraging RWE/RWD to inform their pricing and reimbursement decisions, market access strategies, and product development pipelines, leading to a significant growth in demand for HEOR services that incorporate RWE/RWD.
